Forte Biosciences, Inc. Stock: price and insider trades · United States

From a competitive standpoint, Forte operates in a crowded biotechnology landscape where many companies are pursuing differentiated immunology or inflammation assets. Forte’s comparative advantage is its mechanistic focus and the way it links preclinical validation to early clinical signals. The company has highlighted positive phase 1b data in celiac disease, with a phase 2 study initiated in the second half of 2025 and topline data expected in 2026. It has also stated that phase 1b trials in vitiligo and alopecia areata are enrolling, with results expected in 2026. These milestones are central to the investment thesis because they may confirm whether FB102 can function as a multi-indication therapeutic platform rather than a single-disease asset. ([fortebiorx.com](https://www.fortebiorx.com/investor-relations/default.aspx/1000/))

Geographically, Forte remains mainly U.S.-centric in operations and capital-market exposure, although the diseases it targets have global prevalence. A key risk factor is listing status and funding: in its annual report, the company disclosed non-compliance with Nasdaq’s minimum bid-price requirement and warned that delisting could remain a possibility if compliance is not restored. More recently, Forte published its 2025 results and continued to update investors on the clinical progress of FB102. For investors tracking SEC Form 4 insider transactions, that backdrop is important because insider activity is occurring against a company-specific catalyst cycle and a still-financing-dependent balance sheet. Overall, Forte is a high-risk, event-driven NASDAQ biotech in the United States, with upside tied to clinical execution and downside tied to trial failure or capital dilution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1419041/000119312524188990/d814293dars.pdf))